Sunscreen Chemical BP-3 Accelerates Joint Aging by Triggering Chondrocyte Senescence
A common UV-filter found in sunscreens drives osteoarthritis progression by activating a cellular aging pathway in cartilage cells.
Summary
Benzophenone-3 (BP-3), a UV-absorbing chemical found in many sunscreens and personal care products, has been linked to osteoarthritis (OA) in epidemiological studies. New research now reveals a molecular mechanism: BP-3 induces premature senescence in chondrocytes — the cells that maintain cartilage — by selectively activating the ERK1/2 signaling pathway. This triggers downstream phosphorylation of p53 and the transcription factor Elk-1, driving expression of senescence markers p16, p21, and p53, while simultaneously degrading the extracellular matrix that keeps joints healthy. Blocking ERK with a specific inhibitor reversed these effects, pointing to a targetable pathway and raising new questions about everyday chemical exposures and joint health.
Detailed Summary
Osteoarthritis affects hundreds of millions globally, yet environmental contributors beyond age and obesity remain poorly understood. Benzophenone-3 (BP-3) is one of the most widely used UV filters in sunscreens and cosmetics, and while it is readily absorbed through the skin, its systemic health effects — including potential endocrine disruption — have raised growing concern. Epidemiological data has hinted at a connection between BP-3 exposure and OA prevalence, but the biological mechanism has remained elusive until now.
Researchers exposed rats to prolonged BP-3 and observed OA-like cartilage degeneration, including structural disorganization, proteoglycan depletion, and disrupted extracellular matrix (ECM) homeostasis. Elevated matrix metalloproteinases (MMPs) and reduced type II collagen (Col2a1) — hallmarks of cartilage breakdown — were found both in animal tissue and in human C28/I2 chondrocytes treated with BP-3 in vitro, providing strong cross-model consistency.
Transcriptomic analysis identified senescence-associated gene changes as a central feature of BP-3 exposure. Chondrocytes showed elevated SA-β-galactosidase activity and upregulation of canonical senescence markers p16, p21, and p53. Further pathway analysis pinpointed selective activation of the ERK1/2 arm of the MAPK cascade — notably without activating p38 or JNK. BP-3 appeared to drive p21 transcription via a dual ERK-dependent mechanism: phosphorylating p53 at Ser15 and promoting nuclear translocation of Elk-1, a downstream ERK effector.
Critically, the ERK-specific inhibitor PD98059 blocked BP-3-induced senescence and ECM degradation, validating ERK as the operative pathway. These findings suggest that environmental BP-3 exposure could be a modifiable risk factor for OA progression.
Caveats remain: the study relies on cell lines and rodent models, and human epidemiological confirmation of this specific mechanistic pathway is still needed. Real-world BP-3 exposure levels versus experimental doses also require careful comparison.
Key Findings
- BP-3 exposure induced OA-like cartilage degeneration in rats, including proteoglycan loss and elevated MMPs.
- BP-3 triggered chondrocyte senescence via elevated SA-β-gal, p16, p21, and p53 in human chondrocyte cell lines.
- BP-3 selectively activated ERK1/2 within the MAPK cascade, leaving p38 and JNK unaffected.
- ERK drove senescence via dual mechanism: p53 Ser15 phosphorylation and Elk-1 nuclear translocation.
- ERK inhibitor PD98059 reversed BP-3-induced senescence and cartilage matrix degradation.
Methodology
The study used in vivo rat models with prolonged BP-3 exposure and in vitro human C28/I2 chondrocyte cultures. Transcriptomic and cellular transcriptomic analyses were performed to identify pathway changes, supplemented by senescence assays and pharmacological ERK inhibition with PD98059.
Study Limitations
Findings are based on rodent models and an immortalized human chondrocyte cell line, which may not fully reflect human OA pathophysiology. The BP-3 doses used experimentally may exceed typical human exposure levels, and long-term epidemiological validation of this specific ERK-senescence mechanism in humans is lacking.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: